Aravive Reports P-III Trial (AXLerate-OC) Results of Batiraxcept for Platinum-Resistant Ovarian Cancer
Shots:
- The P-III trial (AXLerate-OC) evaluating the safety and efficacy of batiraxcept in 366 patients with Pt-resistant ovarian cancer
- The trial failed to meet its 1EPs of PFS in the pre-specified subset of patients naïve to prior bevacizumab treatment & did not show any difference b/w two arms in the overall population (incl. patients previously treated with bevacizumab). The company seeks to determine the next steps in the development of batiraxcept & will continue to assess the complete dataset
- In the bevacizumab-naïve & overall population, m-PFS was 5.4 & 5.1mos. in batiraxcept + paclitaxel arm vs 5.4 & 5.5mos. in paclitaxel. The safety profile was consistent with prior studies with no new safety signals
Ref: Aravive | Image: Aravive
Related News:- Aravive Reports Updated Results of Batiraxcept in the P-Ib Study for the Treatment of Clear Cell Renal Cell Carcinoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
